Previous 10 | Next 10 |
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has published the final results of its phase 2b study of patients with Dupuytren’s disease. T...
The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 months The treatment arm showed that nodules continued to soften and regress at the 18-month fol...
The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 months The treatment arm showed that nodules continued to soften and regress at the 18-month fol...
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has formed a scientific advisory board (“SAB”). Initial board members include the...
PALO ALTO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases,...
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released a letter to shareholders from its Chief Executive Officer James Woody, MD, PhD. In the let...
PALO ALTO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis ...
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, will be participating in next year’s Biotech Showcase 2022 Virtual Conference. The online eve...
PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases,...
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has entered into a license agreement with the University of Oxford. The exclusive global agreement o...
News, Short Squeeze, Breakout and More Instantly...
180 Life Sciences Corp Com Company Name:
ATNF Stock Symbol:
NASDAQ Market:
180 Life Sciences Corp Com Website:
180 Life Sciences (NASDAQ: ATNF) today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “hearings panel”) of the Nasdaq Stock Market LLC that it has granted the company’s request for additional time to achieve compliance with Nasdaq’...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq S...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 2.5% to $131.38 on volume of 280,159,738 shares Maxeon Solar Technologies Ltd. (MAXN) fell 8.1% to $0.248 on volume of 217,585,873 shares Tesla Inc. (TSLA) rose 3.7% to $262.33 on volume of 159,323,492 s...